Evaluation of the influence of genetic polymorphisms and clinical factors on torasemide dosing in patients with heart failure

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Heart failure (HF) is a significant problem in modern medicine. Loop diuretics are used in 80–90% of patients with HF, representing a long-established basis for symptomatic treatment. However, many complex and unresolved issues for evidence-based medicine regarding diuretic therapy in HF remain. Given the genetic polymorphism of proteins involved in the metabolism and transport of torasemide, a loop diuretic widely used in clinical practice, as well as the importance of optimal dosing of diuretic therapy in patients with HF, it is necessary to personalize treatment and identify factors influencing diuretic therapy.

Objective. Evaluation of the influence of clinical factors and polymorphisms of the CYP2C9*2 (rs1799853, c.430C>T, Arg144Cys), CYP2C9*3 (rs1057910, 1075A>C, Ile359Leu) and SLCO1B1*5 (rs4149056, c.521T>C, Val174Ala) genes on the dosing of torasemide in patients with HF.

Methods. The study included 68 patients hospitalized with HF who received torasemide as diuretic therapy. Therapy adjustment was performed during hospitalization based on clinical, laboratory and instrumental data. Allelic variants of the CYP2C9 and SLCO1B1 genes were determined by real-time PCR.

Results. The distribution of CYP2C9 gene genotypes in the study population was as follows: 52 (76.5%) patients had the CYP2C9*1/*1 genotype, 9 (13.2%) – CYP2C9*1/*2, 6 (8.8%) – CYP2C9*1/*3, 1 (1.5%) – CYP2C9*2/*2, and the distribution of SLCO1B1*5: 46 (67.6%) – TT, 16 (23.5%) – TC and 6 (8.8%) – CC. The frequency of alleles and genotypes of CYP2C9*2 (χ2=0.82; p=0.66), CYP2C9*3 (χ2=0.14; p=0.93) and SLCO1B1*5 (χ2=5.35; p=0.07) corresponded to the Hardy–Weinberg equation; 30 (44.1%) patients did not require dose adjustment of torasemide, 14 (20.6%) patients required dose increase, 6 (8.8%) patients required dose decrease, 5 (7.4%) patients required loop diuretic therapy discontinued, and 13 (19.1%) patients were replaced with furosemide. Comparison of diuretic therapy depending on CYP2C9 (p=0.879) and SLCO1B1 (p=0.297) genotypes revealed no statistically significant differences. The need to replace torasemide with furosemide was statistically significantly higher in patients with more severe manifestations of HF (p=0.002), renal failure (p=0.020) and polypharmacy (p=0.001). Progression of the HF stage increases the chances of increasing the dose of torasemide or replacing it with furosemide by 4.94 times (95% CI 1.92–12.69); an increase in serum creatinine by 1 μmol/l increases the chances of increasing the dose of torasemide or replacing it with furosemide by 1.02 times (95% CI 1.01–1.04).

Conclusion. Polymorphisms of the CYP2C9*2, CYP2C9*3 and SLCO1B1*5 genes did not demonstrate a statistically significant association with the features of torasemide dosing in patients with HF in the current study. The stage of HF and the serum creatinine level had a direct relationship with the probability of increasing the dose of torasemide or replacing it with furosemide.

Full Text

Restricted Access

About the authors

N. M. Gafurova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: nupa@mail.ru
ORCID iD: 0000-0001-5897-3532
SPIN-code: 9049-3287

Postgraduate Student, Department of Clinical Pharmacology and Propaedeutics of Internal Medicine

Russian Federation, Moscow

R. E. Kazakov

Scientific Center for Expertise of Medical Products

Email: nupa@mail.ru
ORCID iD: 0000-0003-0802-4229
SPIN-code: 8751-5090
Russian Federation, Moscow

E. V. Shikh

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: nupa@mail.ru
ORCID iD: 0000-0001-6589-7654
SPIN-code: 2397-8414
Russian Federation, Moscow

References

  1. Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015;385(9970):812–24. doi: 10.1016/S0140-6736(14)61889-4.
  2. Поляков Д.С., Фомин И.В., Беленков Ю.Н. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА –ХСН. Кардиология. 2021;61(4):4–14. [Polyakov D.S., Fomin I.V., Belenkov Yu.N., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.)]. doi: 10.18087/cardio.2021.4.n1628.
  3. Российское кардиологическое общество. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. [Russian Society of Cardiology. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.)]. doi: 10.15829/1560-4071-2020-4083.
  4. Mullens W., Damman K., Harjola V.P., et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 Feb;21(2):137–55. doi: 10.1002/ejhf.1369.
  5. Galve E., Mallol A., Catalan R., et al. Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction. Eur J Heart Fail. 2005;7(5):892–8. doi: 10.1016/j.ejheart.2004.09.006.
  6. Greene S.J., Mentz R.J. Potential advantages of torsemide in patients with heart failure: more than just a ‘water pill’? Eur J Heart Failure. 2018;20(3):471–3. doi: 10.1002/ejhf.1024.
  7. Chioncel O., Mebazaa A., Harjola V.P., et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(10):1242–54. doi: 10.1002/ejhf.890.
  8. Pham D., Grodin J.L. Dilemmas in the Dosing of Heart Failure Drugs: Titrating Diuretics in Chronic Heart Failure. Card Fail Rev. 2017;3(2):108–12. doi: 10.15420/cfr.2017:10:1.
  9. Cosin J., Diez J., TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507–13. doi: 10.1016/s1388-9842(02)00122-8.
  10. Tsutamoto T., Sakai H., Wada A., et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2004;44(11):2252–3. doi: 10.1016/j.jacc.2004.09.009.
  11. Vormfelde S.V., Toliat M.R., Schirmer M., et al. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;83(6):815–7. doi: 10.1038/sj.clpt.6100404.
  12. Vormfelde S.V., Engelhardt S., Zirk A., et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther. 2004;76(6):557–66. doi: 10.1016/j.clpt.2004.08.024.
  13. Vormfelde S.V., Schirmer M., Hagos Y., et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol. 2006;62(3):323–35. doi: 10.1111/j.1365-2125.2006.02655.x.
  14. Vormfelde S.V., Brockmöller J. The genetics of loop diuretic effects. Pharmacogenom J. 2012;12(1):45–53. doi: 10.1038/tpj.2010.68.
  15. Мубаракшина О.А., Сомова М.Н., Батищева Г.А. Фармакогенетика варфарина: современное состояние вопроса. Consilium Medicum. 2019;21(10): 74–78. [Mubarakshina O.A., Somova M.N., Batishcheva G.A. Pharmacogenetics of warfarin: current status of the issue. Consilium Medicum. 2019;21(10):74–78. (In Russ.)]. doi: 10.26442/20751753.2019.10.190412.
  16. Сычев Д.А. Рекомендации по применению фармакогенетического тестирования в клинической практике. Качественная клиническая практика. 2011;(1):3–10. [Sychev D.A. Recommendations for the use of pharmacogenetic testing in clinical practice. Kachestvennaya Klinicheskaya Praktika=Good Clinical Practice. 2011;(1):3–10. (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Odds ratio estimates with 95% CI for the studied predictors of increasing the dose of torasemide or replacing it with furosemide

Download (63KB)
Indexing metadata

Copyright (c) 2024 Bionika Media